RxDoctor Payments Data

Amol Takalkar, MD

Nuclear Medicine · Shreveport, LANPI 1619931060

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $6,063 of the $8,766 with a category attached, or 69.2%. Progenics Pharmaceuticals, Inc. accounts for 70.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $7,479 and has fallen 87.6% since, to $926 in 2025.

$8,766in general payments, 2019–2025

Across 28 payments — averaging $313.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Progenics Pharmaceuticals, Inc.$6K
  • Telix Pharmaceuticals$2K
  • GE HealthCare$154
  • Cardiva Medical, Inc.$103
  • Alnylam Pharmaceuticals Inc.$86
  • Novartis$56
  • plus $168 from 6 others
$791,567in research payments, 2019–2025

Across 36 payments — averaging $21,988 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$563K
  • Progenics Pharmaceuticals, Inc.$154K
  • GE HealthCare$50K
  • Novartis$13K
  • Bayer$12K

What the payments were for

  • Speaking & faculty fees$6,06369%
  • Travel & lodging$1,61318%
  • Food & beverage$1,07212%
  • Education$180%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear medicine providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$43,951
Medicare patients
663
Services billed
728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nuclear medicine in Shreveport

Where these figures come from

Is this you, or does something look wrong? →